JNJ Q3 adjusted EPS $2.66 rises 19% YoY; $21.7B gain from Kenvue separation

JOHNSON & JOHNSON

2023-Q3 EPS reported $11.95 revenue$63,764,000,000

Q3 sales $21.35B (+6.8% YoY); adjusted diluted EPS $2.66 (+19.3% YoY from $2.23).
Innovative Medicine revenue $13.89B (+5.1% reported); MedTech $7.46B (+10.0%).
U.S. sales grew 11.1% to $11.996B; international sales rose 1.6% to $9.355B.
Discontinued ops net earnings $21.7B (incl. gain from Kenvue separation) vs $148M prior year.
Adjusted pretax income from continuing ops $8.03B, up 13.8% YoY.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.